Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marian Loffredo

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|June 7, 2011
Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen levelJessica J Park, Ming-Hui Chen, Marian Loffredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancerAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
The Journal of Urology|November 12, 2003
Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen eraAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
Clinical Genitourinary Cancer|April 12, 2015
Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRIRavi A Chandra, Ming-Hui Chen, Danjie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen levelAnthony V D'Amico, Marian Loffredo, Andrew A Renshaw, et al.
Prostate Cancer|April 3, 2014
Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trialRavi A Chandra, Ming-Hui Chen, Danjie Zhang, et al.
The Journal of Urology|March 12, 2003
Pretreatment predictors of time to cancer specific death after prostate specific antigen failureAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
Cancer|December 20, 2002
Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinomaAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2009
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of deathAnthony V D'Amico, Ming-Hui Chen, Andrew A Renshaw, et al.
JAMA|January 24, 2008
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trialAnthony V D'Amico, Ming-Hui Chen, Andrew A Renshaw, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|June 7, 2011
Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen levelJessica J Park, Ming-Hui Chen, Marian Loffredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancerAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
The Journal of Urology|November 12, 2003
Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen eraAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
Clinical Genitourinary Cancer|April 12, 2015
Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRIRavi A Chandra, Ming-Hui Chen, Danjie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen levelAnthony V D'Amico, Marian Loffredo, Andrew A Renshaw, et al.
Prostate Cancer|April 3, 2014
Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trialRavi A Chandra, Ming-Hui Chen, Danjie Zhang, et al.
The Journal of Urology|March 12, 2003
Pretreatment predictors of time to cancer specific death after prostate specific antigen failureAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
Cancer|December 20, 2002
Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinomaAnthony V D'Amico, Kerri Cote, Marian Loffredo, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2009
Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of deathAnthony V D'Amico, Ming-Hui Chen, Andrew A Renshaw, et al.
JAMA|January 24, 2008
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trialAnthony V D'Amico, Ming-Hui Chen, Andrew A Renshaw, et al.
Pageof 6